Ann: Preliminary Final Report and Financial State, page-2

re: Ann: Preliminary Final Report and Financi... Nice outlook

"FY 2014 Outlook
Charles Walker, Alchemia’s CEO, commented, “It is exciting to see the progress made over the year across
our assets, and in particular taking fondaparinux and HA-Irinotecan to major value points. HA-Irinotecan is
near the completion stage of its pivotal Phase III trial, with top line results expected in H1 CY 2014. Our first
drug to market, fondaparinux, now has established revenue streams with the potential for further growth
through new market approvals and cost reductions. We are now aggressively pursuing the various options
open to us to maximise the shareholder value for both these assets. FY 14 promises to be a watershed year
for Alchemia.”"